Immunethep, Cantanhede, Portugal
www.immunethep.com/

Immunethep is developing a conjugated peptide-based vaccine to prevent infections from all invasive serotypes of Escherichia coli. With CARB-X support, they will further work on its platform technology to develop an optimized formulation that is able to induce a robust and long-lasting immunity to E. coli. If successful, the vaccine would have broad spectrum capabilities in also preventing infections caused by Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus agalactiae and Streptococcus pneumoniae.

There is no vaccine available for E. coli. Invasive E. coli infections pose a significant public health threat, as certain strains can spread beyond the gastrointestinal tract into the bloodstream, urinary system, and other organs, leading to serious and life-threatening conditions, including sepsis, meningitis, pneumonia, and intra-abdominal infections. E. coli is one of the leading causes of bloodstream infections globally, particularly in healthcare settings. Vulnerable populations, such as the elderly, immunocompromised individuals, and those with chronic health conditions, are at greater risk for severe outcomes. The increasing prevalence of antibiotic-resistant E. coli further reduces treatment options, highlighting the urgent need for effective preventative measures and improved diagnostics to avert and manage these potentially deadly infections.

Current Development Stage: Lead Optimization

CARB-X Investment: Initial investment of US$2M

Initial CARB-X Investment Date: February 25, 2025